Why the study?
Sacubitril/valsartan is changing real-world treatment across heart failure, prompting a synthesis of recent evidence on patient-centered outcomes from randomized controlled trials and associated studies.
Does sacubitril/valsartan improve patient-centered outcomes in patients with heart failure?
Does sacubitril/valsartan improve patient-centered outcomes in patients with heart failure?
This review highlights the expanding role of sacubitril/valsartan across the entire spectrum of heart failure.
Supports ARNI expansion across HF spectrum; extends PARADIGM-HF evidence into broader real-world use.
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: